Global Human Microbiome Market Forecast 2018-2022
Driven by the rising prevalence of chronic diseases, focus on early disease detection and diagnosis and growing prevalence of precision medicines, the global human microbiome market is anticipated to exhibit a CAGR of 22.41% between 2022-2026.
The global human microbiome market is segmented on the basis of products, applications, and diseases. The product segment is categorized into Foods, Probiotics, Prebiotics, Medical foods, Drugs, Diagnostic device, and other products. The application segment of the market includes diagnostics and drugs while the Diseases segment includes Obesity, Cancer,Type 2 diabetes, Crohn’s disease, Ulcerative colitis, C. Difficle infection, Dental caries, Lactose intolerance, Recurrent bacterial vaginosis and UTI, Hyperoxaluria, Skin disorders,Celiac disease, Phenylketonuria, Urea cycle disorder, Hepatic encephalopathy and Non-alcoholic Steatohepatitis.
Regionally, the market is segmented into Asia-Pacific, Europe, North America and rest of the world. By the end of 2026, the North American market is anticipated to dominate the global scene owing to the massive on-going research and increasing funding by several private companies and research institutes. Leading this region is the United States human microbiome market, which is home to several market giants. However, the Asia-Pacific human microbiome market is exhibiting a surging trend, boosted by the heavy funding in the region. China and Japan are at the forefront of this region, and these countries have undertaken several initiatives to augment the methods for the assessment of various biological phenomenon by standardizing various procedures and protocols.
Few of the well-known companies engaged in the global human microbiome market include Avidbiotics Inc., 4d Pharma, Actogenix Nv (Acquired By Intrexon Corporation), Enterome Sa, Avidbiotics Corp, Metabiomics, Metabogen Ab, Microbiome Therapeutics, Miomics, Rebiotix, Osel Inc, Ritter Pharmaceuticals Inc, Symberix Inc, Second Genome, Symbiotix Biotherapies Inc, and Vedanta Biosciences Inc.(Acquired By Puretech Health Plc).